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Incorporation of Glucose Analogs by GtfE and GtfD
from the Vancomycin Biosynthetic Pathway
to Generate Variant Glycopeptides
can precursors from D-Ala-D-Ala termini to D-Ala-D-
lactate termini [3]. The altered termini have low affinity
for the glycopeptide antibiotics [4, 5].
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Madison, Wisconsin 53705 encode three glycosyltransferases (GtfA, GtfB, and
GtfC) [8, 9] that decorate the crosslinked aglycone scaf-3 Department of Chemistry
Princeton University fold with a glucosyl moiety from NDP-glucose (GtfB) or
L-4-epi-vancosaminyl group from NDP-L-4-epi-vanco-Princeton, New Jersey 08544
samine (GtfA, GtfC). Vancomycin has two sugars
attached as an L-vancosaminyl-1,2-D-glucosyl disac-
charide to residue four, 4-hydroxyphenylglycine, of theSummary
heptapeptide scaffold, and it has been previously estab-
lished that GtfE is the D-glucosyltransferase [8, 9] andAnalogs of the glycopeptide antibiotics vancomycin
GtfD is the L-vancosaminyltransferase [9]. It has alsoand teicoplanin with alterations in one or both sugar
been shown that GtfE in particular is efficient at utilizingmoieties of the disaccharide have been prepared by
both the vancomycin and teicoplanin aglycones [8, 9]tandem action of the vancomycin pathway glycosyl-
for transfer of glucose from a TDP-glucose donor.transferases GtfE and GtfD. All four regioisomers (2-,
Multiple examples of sugar-flexible glycosyltransfer-3-, 4-, 6-) of TDP-deoxyglucoses and UDP/TDP-amino-
ases involved the biosynthesis of the polyketide classglucoses were prepared, predominantly by action of
of antibiotics have been identified (as reviewed in [10]).D-glucopyranosyl-1-phosphate thymidylyltransferase,
Using these glycosyltransferases in gene-swapping andEp. GtfE transferred the deoxyglucoses or aminoglu-
engineering experiments in antibiotic-producing organ-coses onto the 4-OH of 4-hydroxyphenylglycine of
isms for in vivo combinatorial biosynthesis has gener-both the vancomycin and teicoplanin aglycone scaf-
ated numerous novel glycosylated compounds derivedfolds. Kinetic analysis indicated the 2-, 3-, 4-, and
from such natural products as erythromycin, ellora-6-amino-glucoses were transferred by GtfE with only
mycin, and urdamycin [11–14].a 4- to 30-fold drop in kcat and no effect on Km compared
To evaluate the prospect of using some or all of theto the native substrate, UDP/TDP-glucose, suggesting
five Gtfs involved in vancomycin and chloroeremomycinpreparative utility. The next enzyme, GtfD, could utilize
biosynthesis in vitro for combinatorial biosynthesis ofthe variant glucosyl-peptides as substrates for trans-
new glycopeptide antibiotics with altered sugars re-fer of L-4-epi-vancosamine. The aminosugar moieties
quires a supply of such D-glucose and L-vancosamine/in these variant glycopeptides introduce sites for acy-
4-epi-vancosamine analogs at the NDP-sugar level. Inlation or reductive alkylation.
this study, we have synthesized some UDP-glucose an-
alogs and also utilized the previously described promis-
Introduction cuity of -D-glucopyranosyl-1-phosphate thymidylyl-
transferase, designated Ep [15–17], to produce a seriesThe two glycopeptide antibiotics in clinical use for the of TDP-deoxyglucoses and TDP-aminoglucoses. These
treatment of life-threatening gram-positive bacterial in- were then tested as substrates, first for GtfE, to generate
fections are vancomycin (1) and teicoplanin (2) (Figure 1), the monoglycosylated peptide scaffold, and then with
related nonribosomal heptapeptides that are oxidatively GtfD, to build analogs of the disaccharide chain on both
crosslinked, differentially glycosylated, and in the case the vancomycin and teicoplanin scaffolds.
of teicoplanin, N-acylated on an aminosugar. As both
vancomycin and teicoplanin have become front-line
drugs for treating enterococcal infections, resistance Results
has arisen [1]. VanA phenotypes of vancomycin-resis-
tant enterococci (VRE) are resistant to both drugs, while Chemical Synthesis of UDP-Glucose Derivatives
VanB phenotypes are resistant to vancomycin but re- Six glucose-1-phosphate analogs were coupled to the
main sensitive to teicoplanin. This difference arises by nucleotide uridine monophosphate to produce three an-
selective failure of teicoplanin to induce transcription of alogs replacing the position 2 hydroxyl of glucose with
the VanHAX genes [2], which in turn remodel peptidogly- fluoro, azido, and amino groups (UDP-2-fluoro-glucose,
UDP-2-azido-glucose, and UDP-2-amino-glucose) and
three analogs replacing the position 6 hydroxyl of glu-4Correspondence: christopher_walsh@hms.harvard.edu
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Figure 1. Structures of Vancomycin, Teicoplanin, Oritavancin, and Chloroeremomycin
cose (UDP-6-chloro-glucose, UDP-6-azido-glucose, mM TDP-3-deoxy-glucose, and approximately 2 mM solu-
tions of TDP-4-deoxy-glucose and TDP-6-deoxy-glucose.UDP-6-amino-glucose) as potential substrates for GtfE
and the aglycones of teicoplanin or vancomycin. The syn- The double-variant glucose derivative, TDP-4-amino-6-
deoxy-glucose, was also made using Ep-mediated con-thetic approach to generate these compounds is shown
in Figure 2. Starting with the corresponding acetylated version of the corresponding sugar-1-phosphate in
80%–90% yield, resulting in a final concentration of 2lactols (5a, 5b, 9a–c), the 3,4-acetoxy sugar-1-phosphates
(6a, 6b, 10a–c) were generated by phosphorylation, and mM in subsequent incubations with GtfE.
Since the chemical coupling noted above gave UDP-subsequent coupling using UMP-morpholidate resulted
in the six UDP-glucose derivatives (7a, 7b, 8, 11a, 11b, 2-amino-glucose and UDP-6-amino-glucose, we pre-
pared the other two regiosiomers enzymatically as the12), with overall yields between 18%–32% (Figure 2)
[18]. The purity and identity of each compound was TDP-sugars by Ep-mediated conversions of 3-amino-
glucose-1-phospate and 4-amino-glucose-1-phosphateverified by mass spectrometry (EI) and 1H-, 13C-, and 31P-
NMR (data not shown). [17] to produce TDP-3-amino-glucose and TDP-4-amino-
glucose in 80%–90% yields in the 3 hr incubations.
Large-scale incubations were performed to generate 18Chemoenzymatic Synthesis of TDP-Glucose
mg of TDP-3-amino-glucose and 3.5 mg of TDP-4-Derivatives
amino-glucose after purification for further studies toIn parallel to the chemical syntheses noted above, we
determine kinetic parameters with GtfE.evaluated the ability of the thymidylyl transferase Ep to
Thus, all four regioisomers of TDP-deoxyglucose andtake a variety of D-glucose-1-P derivatives for thymidylyl
NDP-aminoglucose, as well as the doubly variant TDP-transfer catalysis (Figure 3), building on prior efforts that
4-amino-6-deoxy-glucose and the 6-desmethyl-glu-suggested relaxed specificity could be expected [16,
cose, UDP-xylose (Figure 4), were available for testing17]. In the deoxy series, the 2-, 3-, 4-, and 6-deoxyglu-
as sugar donors for GtfE catalysis.cose-1-phosphate species were prepared as previously
described [17] and were shown to be thymidylylated by
Ep to the TDP-sugar products as evaluated by HPLC Transfer of Glucose Derivatives by GtfE to the
Vancomycin and Teicoplanin Aglyconesanalysis (data not shown). Under the incubation condi-
tions noted in the experimental section, we observed The ten UDP- and TDP-glucose derivatives shown in
Figure 4, as well as UDP-2- and 6-azido-glucose, UDP-70%–100% conversion to 4- and 6-deoxy-glucosyl-TDP
species, while the TDP-2-deoxy-glucose was generated 2-fluoro-glucose, and UDP-6-chloro-glucose were as-
sayed as substrates for pure GtfE with both its nativein only about 10% yield, and TDP-3-deoxy-glucose was
generated in about 30% yield. In incubations for subse- aglycone heptapeptide substrate (AGV, vancomycin
aglycone) and also with the teicoplanin aglycone (AGT,quent reaction with GtfE and aglycones, this resulted in
250 M TDP-2-deoxy-glucose in the GtfE reaction, 0.75 teicoplanin aglycone), which differs in amino acids 1 and
Substrate Flexibility of Vancomycin GtfE and GtfD
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Figure 2. Synthesis of UDP-Glucose Derivatives
(A) Synthesis of UDP-2-azido-, 6-azido-, and 6-amino-glucose; (B) synthesis of UDP-6-chloro-, 2-fluoro-, and 2-amino-glucose. Reagents and
conditions: (a) 1. iPr2NP(OCH2CH2CN)2, tetrazole, CH2Cl2, 40–0C; 2. mCPBA, CH2Cl2, 40–0C; (b) TMG, TMSCl, CH3CN, rt, 1hr; (c) UMP-
morpholidate, tetrazole, pyridine, rt, 48 hr; (d) Et3N/MeOH/H2O (1:2:2), 24 hr; (e) H2, Pd-C, MeOH, 4 hr; (f) 1. iPr2NP(OBn)2, tetrazole,
CH2Cl2, 40–0C; 2. mCPBA, CH2Cl2, 40–0C; (g) NaOMe, MeOH, 1 hr.
3. Glycosylated peptide products were first analyzed by parison of the other UDP- and TDP-glucose analogs.
The 6-deoxydesmethyl (xylose) and the 6-chloromethylHPLC, and new peaks were corroborated for molecular
weight by Maldi-TOF mass spectrometry. Each of the group in UDP-6-chloro-glucose are tolerated at about
9% and less than 0.1% catalytic efficiency, respectively.nucleotide sugar substrates shown in Figure 4B could
be recognized and the sugar moiety transferred by GtfE All Km and kcat data were gathered using the vancomycin
aglycone as the acceptor substrate. The four regioiso-to the vancomycin and teicoplanin scaffolds as analyzed
by HPLC and mass spectrometry, while UDP-2-azido-, meric TDP-deoxyglucoses also served as substrates
and could be transferred not only to the vancomycinUDP-2-fluoro-, and UDP-6-azido-glucose proved inade-
quate for transfer by GtfE. In Figure 5, representative scaffold but also the teicoplanin scaffold. For example,
as shown in Figure 6B, the 4-deoxy-glucosyl-AGT prod-HPLC traces are shown using the donor sugar sub-
strates UDP-glucose, UDP-2-amino-glucose, and UDP- uct (15) could be accumulated and detected by HPLC
analysis of GtfE incubations with AGT and TDP-4-deoxy-6-amino-glucose, showing glycosyl transfer to both the
vancomycin and teicoplanin aglycone acceptor sub- glucose. UDP-2-fluoro-glucose was not detectably pro-
cessed by GtfE, perhaps due to the electronic effectsstrates. Km and kcat data for selected NDP-sugar sub-
strates with GtfE are collected in Table 1. of 2-F on the reactivity at the adjacent C1.
Km and kcat data were obtained for all four regioisomersFirst, both UDP-glucose and TDP-glucose as sub-
strates have equal catalytic efficiency (kcat/Km), indicating of NDP-aminoglucose reacting with the vancomycin
aglycone scaffold and are shown in Table 1. GtfE isthat GtfE is not fastidious about the 5-methyl of thymine
or the 2-hydroxyl of ribose versus deoxyribose. This remarkably permissive for the amino group at carbons
2, 3, 4, and 6 of the glucose ring, with all four NDP-permissivity toward the NDP moiety allows cross com-
Figure 3. Scheme for Ep-Mediated Synthesis of TDP-Glucose
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Figure 4. GtfE Recognition and Transfer of Alternate Nucleotide-Sugar Donors onto the Heptapeptide Acceptor Substrate
(A) Reaction pathway of GtfE; (B) deoxy- and amino-derivatives of NDP-glucose tested.
aminoglucoses having equivalent Km values (0.7–1.2 deoxy-3-methyl-3-amino-hexose. This TDP sugar is not
mM) and also a narrow range of kcat values (1.3–7.1 available for study. However, we have reported both the
min1). Compared to the authentic glucosyl donor sub- biosynthesis of the 4-epi form, TDP-L--4-epi-vanco-
strate, TDP- or UDP-glucose, the 4- to 30-fold reduction samine, by action of five purified enzymes EvaA-E, from
in catalytic efficiency with the four regioisomeric NDP- the biosynthetic operon in the chloroeremomycin pro-
aminoglucoses is almost entirely a kcat effect. The pKa ducer [21], and also the chemical synthesis of the /
of the amine of the aminoglucoses has been reported anomeric mixture of UDP-L-4-epi-vancosamine [9]. The
to be between 7.75–9 [19, 20]. Since the reactions are latter material was available for use in tandem incuba-
all carried out at pH 9, which is at or above the pKa of tions of GtfE and GtfD.
the aminoglucose substrates, it is not yet known whether The tandem action of GtfE and GtfD was attempted
GtfE transfers the aminoglucose moiety with a proton- using TDP-4-amino-glucose and GtfE in the first stage
ated amine or as the free base. Regardless, the ability and UDP-L-4-epi-vancosamine and GtfD in the second
of GtfE to transfer sugars with an amine displayed at stage (Figure 6A). The heptapeptide scaffold used in
many points of the hexose ring periphery indicated that this case was the vancomycin aglycone, and GtfE action
this combination of enzyme and nucleotide sugars resulted in transfer of 4-amino-glucose (13). The product
would be a useful platform for evaluation of the next of GtfE and GtfD action was 4-epi-vancosaminyl-(1,2)-4-
glycosyltransferase, GtfD. amino-glucosyl-AGV (14), containing a 1,2-disaccharide
moiety with two amino sugars (Figure 6A). The tandem
incubation of GtfE and GtfD combines to yield a deriva-Activity of the Second Glycosyltransferase GtfD:
tive of vancomycin with an alteration in each of the twoTransfer of L-4-epi-Vancosaminyl Groups
sugars: an amine derivative of glucose and a position 4to the Glucosylpeptide Variants
epimer of vancosamine.The deoxyglucosyl- and aminoglucosyl-heptapeptide
Tandem incubations of GtfE and GtfD were also car-products from GtfE incubations could thus be evaluated
ried out on the teicoplanin aglycone scaffold. As exem-as substrates for the next enzyme, GtfD, the L-vanco-
plified in the right-hand column of Figure 6B, incubationsaminyltransferase, involved in the maturation of late-
commenced with GtfE and TDP-4-deoxy-glucose tostage biosynthetic intermediates of the vancomycin
yield 4-deoxy-glucosyl-AGT (15). The second stage in-pathway. The natural sugar donor is presumed to be
TDP-L--vancosamine, where vancosamine is a tri- volved UDP-L-4-epi-vancosamine as the donor sub-
Substrate Flexibility of Vancomycin GtfE and GtfD
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Figure 5. Transfer of Aminoglucoses by GtfE
(A) HPLC traces of glucose, 2-amino-glucose,
and 6-amino-glucose being transferred to
vancomycin aglycone. Mass spectrometry
results for 2-amino-glucosyl-AGV, calculated
[M  H]  1304.4, observed [M  H] 
1304.5; for 6-amino-glucosyl-AGV, calculated
1304.4, observed  1304.5.
(B) HPLC traces of glucose, 2-amino-glucose,
and 6-amino-glucose being transferred to tei-
coplanin aglycone. Mass spectrometry re-
sults for 2-amino-glucosyl-AGT, calculated
[M  H]  1359.4, observed [M  Na] 
1381.4; for 6-amino-glucosyl-AGV, calcu-
lated [M  H]  1359.4, observed [M 
Na]  1381.5.
strate and GtfD as the catalyst to produce the novel glucose attached to both the vancomycin and tei-
coplanin heptapeptide scaffolds (data not shown). Eachteicoplanin analog 4-epi-vancosaminyl-(1,2)-4-deoxy-
glucosyl-AGT (16), two sugars which are not normally new product detected by HPLC was subsequently ana-
lyzed by Maldi-TOF mass spectrometry to verify mass.found appended to the teicoplanin heptapeptide scaf-
fold. Both the heptapeptide scaffold and the two sugars
in the disaccharide moiety differ in the two glycopeptide Discussion
variants shown in Figure 6.
Analogous incubations demonstrated that we were In the naturally occurring glycopeptide antibiotics, the
sugars matter: to some extent in determining potency,able to generate derivatives of the vancomycin disac-
charide containing 3-, 4-, and 6-deoxyglucoses and 3-, to a large extent in increasing solubility, to increase
dimerization constants, and to restrict conformational4-, and 6-aminoglucoses, as well as 4-amino-6-deoxy-
Table 1. Steady-State Kinetic Parameters for Purified NDP-Glucose Derivatives
kcat/Km
Substratea Km (mM) kcat (min1) (mM1min1) Relative kcat/Km
UDP-glucose 0.72 	 0.11 31 	 2 43 1
TDP-glucose 0.62 	 0.09 29 	 2 47 1/0.91
UDP-2-NH2-glucose 0.79 	 0.08 2.7 	 0.2 3.4 1/13
TDP-3-NH2-glucose 0.72 	 0.06 7.1 	 0.2 9.9 1/4.3
TDP-4-NH2-glucose 1.1 	 0.1 2.6 	 0.1 2.4 1/18
UDP-6-NH2-glucose 1.2 	 0.2 1.5 	 0.2 1.3 1/33
UDP-xylose 1.8 	 0.2 8.4 	 0.6 4.7 1/9.1
UDP-6-Cl-glucose 21 	 6 0.3 	 0.1 0.014 1/3100
a The acceptor substrate, the vancomycin aglycone, was held constant at 1 mM in each experiment.
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Figure 6. Recognition of Modified Scaffolds by GtfD
(A) Reaction pathway of 4-epi-vancosaminylation by GtfD of the vancomycin scaffold with 4-amino-glucose attached and the corresponding
HPLC traces with no enzyme, GtfE alone (13, calculated [M  H]  1304.4, observed  1304.4), or GtfED (14, calculated [M  H] 
1447.4, observed [M  Na]  1469.5).
(B) Reaction pathway of 4-epi-vancosaminylation by GtfD of the teicoplanin scaffold with 4-deoxy-glucose attached and the corresponding
HPLC traces with no enzyme, GtfE alone (15, calculated [M  H]  1344.3, observed [M  Na]  1366.5), or GtfED (16, calculated [M 
H]  1487.4, observed [M  Na]  1509.2).
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flexibility of the aglycone scaffold [22–24]. The amino group in the disaccharide moiety is in the distal sugar,
the 4-epi-vancosamine, in which the amine is at positiongroups in the aminohexose moieties of both teicoplanin
(glucosamine), 2, and oritavancin (4-epi-vancosamine), 3 of the hexose ring, which is the site of chlorobiphenyl
alkylation to gain activity against VRE. The ability to3, are sites for either natural acylation (teicoplanin) or
semisynthetic alkylation (oritavancin), modifications that move the amino group around the glucose ring to all
four available positions and append to the vancomycinimprove activity against VRE. The ability to generate
additional aminosugar variants of glycopeptides would or teicoplanin scaffold will allow subsequent acylation
to probe any differences in efficacy from differentialbe of particular interest.
As is typical in many glycopeptide and glycosylated placement of the fatty acyl chain [29]. On the vancomy-
cin scaffold, the 2-amino-glucose is likely to be incom-polyketide biosynthetic clusters, the genes for produc-
ing the dedicated aminodeoxysugars and the glycosyl- petent for subsequent chain elongation by GtfE since
that would generate a bridging –NH group to the terminaltransferases that use the TDP-aminodeoxysugars as do-
nors are integral ORFs in those gene clusters [25–27]. vancosamine sugar, and no activity was detected with
GtfD. The other three sites, 3-amino, 4-amino, andOur prior efforts have validated the function of eight
such ORFs in chloroeremomycin biosynthetic cluster [9, 6-amino, are permissive for elongation and should allow
site-specific alkylation/acylation for subsequent evalua-21], encoding five enzymes for conversion of TDP-
4-keto-6-deoxy-glucose to TDP-L-4-epi-vancosamine tion of potency and spectrum against both sensitive and
resistant enterococci, as well as a broader range ofand three enzymes that attach TDP-glucose or TDP-L-
4-epi-vancosamine at three sites to complete antibiotic gram-positive bacterial pathogens.
Experiments investigating tandem action of GtfE, thenmaturation. Likewise, we have established that GtfD and
GtfE, cloned from the vancomycin producer and purified GtfD, were successful, indicating that amino- or deoxy-
hybrid disaccharide chains can be built on both agly-after heterologous expression in Escherichia coli, act in
tandem to generate the disaccharyl chain of vancomy- cone scaffolds. Figure 6 shows that both the 4-amino-
glucosyl-AGV and the 4-deoxy-glucosyl-AGT could becin [9].
In this study, we began with assay of the glucosyl- elongated by transfer of 4-epi-vancosamine by action of
GtfD. Preparatively useful amounts should be obtainabletransferase, GtfE, that adds the first sugar, a D-glucosyl
unit, to the phenolic oxygen of the 4-hydroxyphenylgly- for subsequent acylation and/or reductive alkylation to
test for improved antibacterial properties. The 4-epi-cine residue at position four of the crosslinked hepta-
peptide aglycone scaffold of vancomycin [9]. We have vancosaminyl-4-amino-glucosyl-AGV (14) is representa-
tive of a new subclass of vancomycin/teicoplanin hy-focused initially on the four regioisomeric deoxyglu-
coses and the four corresponding aminoglucose iso- brids with two amino groups in the disaccharide, and
selective alkylation/acylation chemistry should be pos-mers, given the occurrence of deoxy and amino substi-
tutions in the natural sugar chains of glycopeptide sible to evaluate the utility of double substitution against
both antibiotic-sensitive and resistant bacteria.antibiotics [28]. We also evaluated the 6-chloro and 2-
and 6-azido versions of UDP-glucose because of their Analogous experiments showed that heptapeptide
scaffolds with 3-, 4-, and 6-deoxyglucose and 3-, 4-,potential for subsequent chemical elaboration to addi-
tional derivatives after GtfE or GtfE/D tandem action. and 6-amino-glucose attached could be further elon-
gated with 4-epi-vancosamine by GtfD. In addition, theNone of the latter three UDP-sugars were robust sub-
strates for GtfE. Likewise, UDP-2-fluoro-glucose was doubly variant 4-amino-6-deoxy-glucose could also be
elongated by GtfD, suggesting that both GtfE and GtfDnot recognized, probably due to inductive deactivation
at the adjacent C1 position. can tolerate more than a single change. These experi-
ments suggest that the vancomycin glycosyltransfer-The 2-, 3-, 4-, and 6-deoxy-glucosyl-AGV products
from GtfE action could provide differential elements of ases are very good candidates for use in combinatorial
biosynthesis of glycopeptide antibiotics.hydrophobic surface patches on the sugar and might
be of use in combinations to modulate solubility proper- The Gtfs that carry out the last stages of glycopeptide
antibiotic maturation are promising reagents for intro-ties of such glycopeptide variants. Of these four iso-
mers, the 2-deoxy-glucosyl-AGV would be a dead-end duction of structural versatility on complex aglycone
scaffolds. To implement this approach further, fourproduct vis a vis further elongation since the 2-OH of
the glucose moiety is the nucleophile in the next reac- things are required. First is an expanded library of TDP-
D-glucose analogs, where the Ep thymidylyltransferasetion, the vancosaminyl/4-epi-vancosaminyl transfer by
GtfD or GtfC to create the (4-epi)-vancosaminyl-(1,2)- with its engineered relaxation of specificity toward glu-
cose-1-phosphate derivatives should be a particularlyglucosyl linkage. We have demonstrated, as shown in
Figure 6, that the subsequent enzyme GtfD is sufficiently useful reagent [15, 30, 31]. Second will be a library
of TDP-L-vancosamine analogs. Because the sugar ispromiscuous that it can indeed transfer 4-epi-vancos-
amine to a teicoplanin scaffold with a 4-deoxy-glucose of the L-configuration and because the biosynthesis of
TDP-L-sugars are invariably multiple enzymatic stepsmoiety in lieu of glucose.
The regioisomeric aminoglucoses attached to both from TDP-D-glucose [21, 32], a chemical approach to
libraries of TDP-L-hexoses may be the shorter path. Thethe vancomycin and teicoplanin scaffolds are particu-
larly interesting since the amino groups are chemical three most common biochemically generated substitu-
ents that tailor the hexose backbones are deoxy, amino,handles for both natural acylation and synthetic reduc-
tive alkylation to produce lipoglycopeptides. In tei- and C- and N-methyl groups, and these would be good
starting elements in synthetic TDP-L-hexose libraries.coplanin, 2, it is the 2-amino-glucose moiety that is enzy-
matically acylated. In oritavancin, 3, the only amino The third requirement would be for additional variants
Chemistry & Biology
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Experimental Proceduresof the crosslinked aglycone scaffolds as starting sub-
strates for glycosylation. These could include backbone
Synthesis of UDP-2-Amino-Glucose, UDP-2-Azido-Glucose,alterations such as those found in the complestatin agly-
UDP-2-Fluoro-Glucose, UDP-6-Amino-Glucose,
cone [33], O-sulfation found in the naturally occurring UDP-6-Azido-Glucose, and UDP-6-Chloro-Glucose
A47934 antibiotic of the teicoplanin family [8, 34], and The different UDP-glucose derivatives were prepared starting from
the corresponding acetylated lactols (Figure 2) which were obtainedselective semisynthetic alterations at the N and C termini
from the anomeric acetates [41–45] by cleavage with hydrazine ace-of the heptapeptide scaffold, such as found in dalbavan-
tate in DMF. The 2-azido and 6-azido lactols (5a and 5b) were cou-cin [35]. The fourth requirement would be for a broader
pled with dicyanoethyl diisopropylphosphoramidite with tetrazoleset of Gtfs. These could come from as yet uncloned
in dichloromethane (CH2Cl2) and oxidized to the protected 1-phos-glycopeptide biosynthetic clusters that would put in the phates with 3-chloroperbenzoic acid (mCPBA) in CH2Cl2 (40–0C).
other aminodeoxy sugars found in this class of natural Removal of the cyanoethyl groups was achieved by treatment with
tetramethyl guanidine (TMG) and chlorotrimethylsilane (TMSCl) inproducts, such as L-acosamine or L-ristosamine [28].
acetonitrile (CH3CN) at room temperature for 1 hr [46]. The 3,4-Alternatively, recent advances in structure determina-
acetoxy sugar-1-phosphates (6a and 6b) were coupled with UMP-tion of GtfB [36] and the related MurG [37] might suggest
morpholidate using tetrazole as a catalyst in pyridine at room tem-productive reengineering approaches to broaden glyco-
perature for 48 hr. Deacetylation (Et3N/MeOH/H2O, 1:2:2 for 24 hr)syl transfer capacity. gave UDP-2-azido-glucose (7a) and UDP-6-azido-glucose (7b), re-
Finally, libraries of TDP-D-hexoses and TDP-L- spectively. Hydrogenation (H2, Pd-C) for 4 hr in methanol of the 7b
yielded UDP-6-amino-glucose (8) (Figure 2A).hexoses would also be useful substrate collections for
For synthesis of the 6-chloro, 2-fluoro, and 2-amino UDP-glucoseGtfs that transfer glycosyl groups to nonpeptidic agly-
derivatives, a slightly modified reaction scheme was followed (Figurecones such as the 14- and 16-membered polyketide
2). Coupling of the 6-chloro and 2-fluoro lactols (9a and 9b), 2-N-macrolactones, deoxyerythronolactone and tylactone
trifluoroacetyl lactol (9c) with dibenzyl diisopropylphosphoramidite
on the way to erythromycin and tylosin, as well as the with tetrazole in CH2Cl2, oxidation with mCPBA in CH2Cl2 (40–0C),
polycyclic polyketide aglycones, e.g., in the mithramycin and hydrogenation of the benzyl groups (H2, Pd-C) for 4 hr in metha-
nol afforded the 3,4-acetoxy sugar-1-phosphates (10a, 10b, and 10c).and daunomycin families [25, 38–40]. Many of these
Deacetylation with NaOMe in methanol for 1 hr gave an anomericglycosyltransferases have been shown to have sugar
mixture of phosphates, which was coupled with UMP-morpholidatesubstrate flexibility (as reviewed in [10]), but available
[18] using tetrazole as a catalyst in pyridine at room temperaturesugar substrates are limited to those that are made in
for 48 hr to give UDP-6-chloro-glucose (11a), UDP-2-fluoro-glucose
these organisms by large sets of biosynthetic enzymes. (11b), and UDP-2-N-TFA-glucose (11c). UDP-2-amino-glucose (12)
was obtained from 11c following removal of the trifluoroacetyl pro-
tecting group with Et3N/MeOH/H2O (1:2:2) for 24 hr (Figure 2B). ForSignificance
all compounds, identity and purity were verified by 1H-, 13C-, and
31P-NMR and mass spectrometry (EI).We have used a combination of chemical and che-
moenzymatic approaches to generate a library of nu-
Chemoenzymatic Synthesis of TDP-Deoxy- and TDP-cleotide sugar substrates for glycosyltransferases
Aminoglucose Derivatives by Epfrom the vancomycin biosynthetic operon in order to
The procedure for the enzymatic conversion of glucose-1-phos-
evaluate the potential for combinatorial biosynthesis phate to TDP-glucose by the Ep enzyme has been described pre-
within the glycopeptide class of antibiotics. We have viously, as has the ability of Ep to accept many derivatives of glu-
cose-1-phosphate for catalysis [16, 17]. Ep was purified as previouslydemonstrated the ability to incorporate numerous an-
described, and 2-, 3-, 4-, and 6-deoxy- and amino-glucose-1-phos-alogs of NDP-glucose onto the heptapeptide scaffolds
phates as well as 4-amino-6-deoxy-glucose-1-phosphate were syn-of both vancomycin and teicoplanin, including all four
thesized as before [16, 17]. The in vitro reactions were carried out asregioisomeric deoxy- and aminoglucoses, using the
previously described [17], except glucose-1-phosphate derivative
glucosyltransferase GtfE. In addition, subsequent concentrations were 5 mM, TTP concentration was 5 mM, and 5
elaboration of the modified glucosylpeptides with units of inorganic pyrophosphatase were used in each reaction.
Reaction progress was monitored by HPLC (A260) using an Alltech4-epi-vancosamine by the vancosaminyltransferase,
Strong Anion Exchange (SAX) column (250 
 4.6mm) and a linearGtfD, generated vancomycin and teicoplanin deriva-
gradient of 50–250 mM potassium phosphate (pH 5) over 20 min.tives with variant disaccharides. The ability to incorpo-
Large-scale incubations were carried out in order to make andrate all four regioisomeric aminoglucoses allows for
purify TDP-3- and 4-amino-glucose. A 25 ml enzymatic reaction
subsequent selective modification of the amine by containing 25 mg 3-amino-glucose-1-phosphate at a final concen-
chemical acylation or reductive alkylation, which has tration of 3.8 mM was incubated for 3 hr at 37C. Once the reaction
been shown to increase activity against vancomycin- reached 75% completion as monitored by SAX HPLC (see above),
it was quenched by addition of 25 ml cold methanol. After centrifuga-resistant enterococci, as exemplified by the semisyn-
tion, the supernatant was concentrated and then lyophilized. Afterthetic glycopeptide oritavancin. The ability to append
resuspension in 0.5 ml water, the mixture was chromatographed ondisaccharides with two aminosugars onto the vancomy-
a 10 g silica gel column with 1:1 methanol:ammonium hydroxide as
cin and teicoplanin scaffolds, for example the vancomy- the eluent. Fractions were analyzed by silica gel thin layer chroma-
cin heptapeptide with the disaccharide 4-epi-vancos- tography using the same eluent and detected by UV. Fractions con-
amine-(1,2)-4-amino-glucose attached, provides two taining TDP-3-amino-glucose were pooled and concentrated. SAX
HPLC and 31P-NMR analysis were used to verify the purity of thesites for subsequent chemical modification and in-
sample.creases the potential to discover derivatives that are
A 3.2 ml Ep reaction containing 3 mg 4-amino-glucose-1-phos-active against vancomycin-resistant enterococci. The
phate at a final concentration of 3.5 mM was incubated for 2 hr atobserved relaxed specificity of the vancomycin glyco-
37C and quenched with an equal volume of cold methanol. After
syltransferases GtfE and GtfD demonstrates the po- centrifugation, the supernatant was concentrated and purified by
tential for combinatorial biosynthesis within the glyco- HPLC using a Alltech semiprep SAX column (10 
 250 mm) with a
linear gradient of 50–175 mM ammonium acetate (pH 5.5) over 20peptide class of antibiotics.
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min. TDP-4-amino-glucose-containing fractions were pooled and ics: synthesis and antibacterial activity. J. Antibiot. (Tokyo) 49,
575–581.lyophilized, and purity was analyzed by 31P-NMR.
7. van Wageningen, A.M., Kirkpatrick, P.N., Williams, D.H., Harris,
B.R., Kershaw, J.K., Lennard, N.J., Jones, M., Jones, S.J., andIn Vitro Glycosylation Reactions
Solenberg, P.J. (1998). Sequencing and analysis of genes in-Glycosyltransferases GtfE and GtfD were overproduced and purified
volved in the biosynthesis of a vancomycin group antibiotic.as previously described [9]. Reactions were carried out and analyzed
Chem. Biol. 5, 155–162.by HPLC as previously described [9]. In brief, synthetic UDP-glucose
8. Solenberg, P.J., Matsushima, P., Stack, D.R., Wilkie, S.C.,derivatives were added to a final concentration of 5 mM in a 100 l
Thompson, R.C., and Baltz, R.H. (1997). Production of hybridreaction, and 50 l of the Ep reaction mixture to make each TDP-
glycopeptide antibiotics in vitro and in Streptomyces toyo-glucose derivative was added to make a final reaction volume of
caensis. Chem. Biol. 4, 195–202.100 L. Each 100 l reaction contained either 1 mM vancomycin
9. Losey, H.C., Peczuh, M.W., Chen, Z., Eggert, U.S., Dong, S.D.,aglycone or 0.5 mM teicoplanin aglycone. The final concentration
Pelczer, I., Kahne, D., and Walsh, C.T. (2001). Tandem actionof GtfE and GtfD in each reaction was 5 M. Reactions with GtfD
of glycosyltransferases in the maturation of vancomycin andalso contained 2 mM UDP-L-4-epi-vancosamine. Fifty microliter
teicoplanin aglycones: novel glycopeptides. Biochemistry 40,time points were taken at 0 and 20 hr and quenched with 9 vol
4745–4755.methanol. After centrifugation, the supernatants were dried and re-
10. Mendez, C., and Salas, J.A. (2001). Altering the glycosylationsuspended in water for HPLC analysis. All glycosylation reactions
pattern of bioactive compounds. Trends Biotechnol. 19,were monitored by UV (285 nm) using a Vydac C18 small-pore col-
449–456.umn with a linear gradient of 0%–20% acetonitrile in water with
11. Blanco, G., Patallo, E.P., Brana, A.F., Trefzer, A., Bechthold, A.,0.1% trifluoracetic acid. The molecular weight of new products was
Rohr, J., Mendez, C., and Salas, J.A. (2001). Identification of aanalyzed by Maldi-TOF mass spectrometry using a Perseptive Bio-
sugar flexible glycosyltransferase from Streptomyces olivaceus,systems Voyager-DE STR mass spectrometer.
the producer of the antitumor polyketide elloramycin. Chem.In order to determine steady-state kinetic parameters of GtfE,
Biol. 8, 253–263.the concentrations of each sugar listed in Table 1 were varied. All
12. Gaisser, S., Reather, J., Wirtz, G., Kellenberger, L., Staunton, J.,reactions were carried out with 1 mM vancomycin aglycone as the
and Leadlay, P.F. (2000). A defined system for hybrid macrolide
acceptor substrate. For UDP- and TDP-glucose, [GtfE] was 50 nM,
biosynthesis in Saccharopolyspora erythraea. Mol. Microbiol.
and the sugar substrates were varied from 0.25–8 mM; for UDP-
36, 391–401.
xylose [GtfE] was 200 nM, and UDP-xylose was varied from 0.5–24
13. Hoffmeister, D., Wilkinson, B., Foster, G., Sidebottom, P.J., Ichi-
mM; for UDP-6-chloro-glucose [GtfE] was 5 M, and the sugar sub-
nose, K., and Bechthold, A. (2002). Engineered urdamycin glyco-
strates were varied from 1–32 mM; for UDP-2-amino-glucose [GtfE]
syltransferases are broadened and altered in substrate specific-
was 150 nM, and UDP-2-amino-glucose was varied from 0.125–8
ity. Chem. Biol. 9, 287–295.
mM; for TDP-3-amino-glucose [GtfE] was 200 nM, and TDP-3- 14. Rodriguez, L., Oelkers, C., Aguirrezabalaga, I., Brana, A.F., Rohr,
amino-glucose was varied from 0.15–6 mM; for TDP-4-amino-glu- J., Mendez, C., and Salas, J.A. (2000). Generation of hybrid
cose [GtfE] was 250 nM, and TDP-4-amino-glucose was varied from elloramycin analogs by combinatorial biosynthesis using genes
0.25–8 mM; and for UDP-6-amino-glucose [GtfE] was 200 nM, and from anthracycline-type and macrolide biosynthetic pathways.
UDP-6-amino-glucose was varied from 0.25–12 mM. Each experi- J. Mol. Microbiol. Biotechnol. 2, 271–276.
ment was performed in duplicate or triplicate. 15. Barton, W.A., Lesniak, J., Biggins, J.B., Jeffrey, P.D., Jiang,
J., Rajashankar, K.R., Thorson, J.S., and Nikolov, D.B. (2001).
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